{"id":"methylphenidate-extended-release-liquid-formulation","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Insomnia"},{"rate":"10-20","effect":"Decreased appetite"},{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"5-10","effect":"Nervousness/anxiety"},{"rate":"5-10","effect":"Tachycardia"},{"rate":"5-10","effect":"Elevated blood pressure"}]},"_chembl":{"chemblId":"CHEMBL796","moleculeType":"Small molecule","molecularWeight":"233.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methylphenidate is a sympathomimetic amine that inhibits the reuptake transporters for dopamine and norepinephrine, leading to increased concentrations of these neurotransmitters in the synaptic cleft. This enhanced dopaminergic and noradrenergic signaling improves attention, focus, and impulse control. The extended-release liquid formulation provides sustained drug delivery over an extended period, allowing for once-daily dosing.","oneSentence":"Methylphenidate blocks the reuptake of dopamine and norepinephrine in the central nervous system, increasing their availability at the synapse.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:46.396Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD) in children and adults"},{"name":"Narcolepsy"}]},"trialDetails":[{"nctId":"NCT02096952","phase":"PHASE4","title":"Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2014-05","conditions":"Attention-deficit/Hyperactivity Disorder, Autism Spectrum Disorder","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Quillivant extended release"],"phase":"marketed","status":"active","brandName":"Methylphenidate extended-release liquid formulation","genericName":"Methylphenidate extended-release liquid formulation","companyName":"Massachusetts General Hospital","companyId":"massachusetts-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Methylphenidate blocks the reuptake of dopamine and norepinephrine in the central nervous system, increasing their availability at the synapse. Used for Attention-deficit/hyperactivity disorder (ADHD) in children and adults, Narcolepsy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}